Brought to you by 
Cytos, Kuros merge to form leader in tissue repair and orthobiologics
20 Jan 2016
Executive Summary
Public Swiss firm Cytos Biotechnology Ltd. and closely held Kuros Biosurgery AG are merging to create leading biosciences company in the tissue repair and regeneration space.
Deal Industry
- Pharmaceuticals
-
Pharmaceuticals
- Vaccines
-
Medical Devices
- Biomaterials
-
Biotechnology
- Gene Therapy, Cell Therapy
- Large Molecule
Deal Status
- Final
Deal Type
-
Acquisition
- Acquisition of Private Biotech
- Full Acquisition
- Intra-Biotech Deal
- Payment Includes Stock
- Reverse Acquisition
Already a Biomedtracker subscriber?
You have access to the full deal record through your subscription
Want to become a subscriber?
Subscribers get more deal details, updates, deal financials and deal products.
Questions?
Questions?
Please contact Sales at: (212) 520-2765 or email [email protected]
Related Companies
You must sign in to use this functionality
Authentication.SignIn.HeadSignInHeader
Cytos, Kuros merge to form leader in tissue repair and orthobiologics
Email Deal
All set! This article has been sent to my@email.address.
All fields are required. For multiple recipients, separate email addresses with a semicolon.
DCD.EmailPopout.Notice